Globalspace Technologies Ltd
Incorporated in 2010, Globalspace Technologies Ltd is in the business of providing technology enabled solutions and allied activities.[1]
- Market Cap ₹ 82.5 Cr.
- Current Price ₹ 24.0
- High / Low ₹ 33.5 / 13.7
- Stock P/E 60.7
- Book Value ₹ 16.3
- Dividend Yield 0.00 %
- ROCE 4.49 %
- ROE 2.46 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company is expected to give good quarter
- Debtor days have improved from 47.5 to 25.8 days.
- Company's working capital requirements have reduced from 183 days to 91.8 days
Cons
- Company has a low return on equity of 1.68% over last 3 years.
- Contingent liabilities of Rs.36.4 Cr.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.80 | 13.98 | 17.28 | 29.18 | 15.34 | 24.91 | 25.03 | 9.11 | 19.27 | 29.05 | 29.32 | 33.01 | |
| 8.99 | 11.10 | 13.63 | 22.89 | 9.09 | 17.05 | 15.30 | 3.43 | 13.15 | 24.25 | 25.67 | 28.98 | |
| Operating Profit | 1.81 | 2.88 | 3.65 | 6.29 | 6.25 | 7.86 | 9.73 | 5.68 | 6.12 | 4.80 | 3.65 | 4.03 |
| OPM % | 16.76% | 20.60% | 21.12% | 21.56% | 40.74% | 31.55% | 38.87% | 62.35% | 31.76% | 16.52% | 12.45% | 12.21% |
| 0.00 | 0.00 | 0.00 | 0.14 | 0.17 | 0.01 | 0.09 | 0.04 | 0.22 | -3.74 | -2.75 | 0.34 | |
| Interest | 0.39 | 0.51 | 0.81 | 0.90 | 0.84 | 0.87 | 0.75 | 1.41 | 2.19 | 1.76 | 1.09 | 0.88 |
| Depreciation | 0.55 | 1.20 | 1.26 | 2.14 | 3.64 | 1.47 | 1.91 | 4.18 | 3.65 | 3.11 | 2.03 | 1.60 |
| Profit before tax | 0.87 | 1.17 | 1.58 | 3.39 | 1.94 | 5.53 | 7.16 | 0.13 | 0.50 | -3.81 | -2.22 | 1.89 |
| Tax % | 3.45% | 47.01% | 34.81% | 31.56% | 43.81% | 24.59% | 20.81% | 100.00% | -4.00% | -7.35% | -17.12% | 27.51% |
| 0.85 | 0.62 | 1.02 | 2.32 | 1.09 | 4.17 | 5.67 | 0.01 | 0.52 | -3.53 | -1.84 | 1.36 | |
| EPS in Rs | 3.04 | 1.77 | 0.40 | 0.67 | 0.32 | 1.21 | 1.65 | 0.00 | 0.15 | -1.03 | -0.54 | 0.40 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 4.04% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 6% |
| 3 Years: | 20% |
| TTM: | 13% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | -25% |
| 3 Years: | 50% |
| TTM: | 48% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -6% |
| 3 Years: | 13% |
| 1 Year: | 54% |
| Return on Equity | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 1% |
| 3 Years: | 2% |
| Last Year: | 2% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.95 | 1.17 | 8.42 | 11.46 | 11.46 | 11.46 | 11.46 | 11.46 | 11.46 | 34.37 | 34.37 | 34.37 |
| Reserves | 3.67 | 5.85 | 1.91 | 20.99 | 18.70 | 19.10 | 24.98 | 24.10 | 21.26 | 22.04 | 20.14 | 21.51 |
| 3.72 | 3.88 | 8.09 | 6.10 | 4.44 | 6.85 | 8.62 | 26.51 | 23.70 | 12.58 | 9.69 | 3.29 | |
| 2.30 | 5.52 | 4.48 | 8.99 | 3.02 | 5.03 | 6.14 | 2.26 | 2.20 | 1.47 | 2.57 | 5.95 | |
| Total Liabilities | 10.64 | 16.42 | 22.90 | 47.54 | 37.62 | 42.44 | 51.20 | 64.33 | 58.62 | 70.46 | 66.77 | 65.12 |
| 3.01 | 1.86 | 6.01 | 13.11 | 8.76 | 7.33 | 14.10 | 22.28 | 20.93 | 20.14 | 10.00 | 26.55 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.96 | 0.99 | 1.41 | 0.45 | 1.98 | 3.54 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 2.10 | 2.10 | 2.10 | 1.01 | 1.01 | 1.53 | 1.53 |
| 7.63 | 14.56 | 16.89 | 34.43 | 28.85 | 31.05 | 34.01 | 38.54 | 36.23 | 47.33 | 51.70 | 37.04 | |
| Total Assets | 10.64 | 16.42 | 22.90 | 47.54 | 37.62 | 42.44 | 51.20 | 64.33 | 58.62 | 70.46 | 66.77 | 65.12 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.68 | -1.00 | 0.74 | 1.62 | -1.33 | 2.23 | 8.14 | -4.88 | 4.47 | -10.49 | -2.03 | 21.87 | |
| -1.27 | -0.06 | -5.37 | -11.92 | -2.43 | -4.09 | -7.63 | -12.18 | 0.21 | -3.86 | 6.03 | -14.62 | |
| 0.52 | 1.08 | 4.58 | 16.99 | -2.53 | 1.54 | 1.58 | 14.85 | -4.68 | 14.34 | -3.98 | -7.27 | |
| Net Cash Flow | -0.07 | 0.02 | -0.05 | 6.70 | -6.28 | -0.31 | 2.09 | -2.20 | 0.00 | 0.00 | 0.02 | -0.02 |
| Free Cash Flow | -0.59 | -1.06 | -4.63 | -7.58 | -3.91 | 0.23 | 0.43 | -17.10 | 3.73 | -14.35 | 4.52 | 7.25 |
| CFO/OP | 51% | -31% | 22% | 50% | 6% | 55% | 96% | -65% | 78% | -202% | -55% | 553% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 159.52 | 197.90 | 260.44 | 237.16 | 339.30 | 146.82 | 161.14 | 527.67 | 244.53 | 42.34 | 74.44 | 25.76 |
| Inventory Days | 40.43 | 314.78 | 154.30 | 42.17 | 86.76 | 201.39 | 155.79 | 3,360.00 | 219.14 | 112.70 | 101.12 | 31.37 |
| Days Payable | 31.19 | 159.95 | 60.66 | 141.07 | 231.86 | 21.12 | 26.86 | 540.00 | 52.30 | 8.19 | 21.96 | 72.08 |
| Cash Conversion Cycle | 168.76 | 352.74 | 354.09 | 138.26 | 194.20 | 327.09 | 290.07 | 3,347.67 | 411.38 | 146.85 | 153.61 | -14.95 |
| Working Capital Days | 45.62 | 142.55 | 157.79 | 137.09 | 416.40 | 274.89 | 147.14 | 465.97 | 192.25 | 194.50 | 262.92 | 91.78 |
| ROCE % | 16.86% | 17.46% | 16.30% | 15.06% | 7.60% | 17.78% | 19.18% | 2.88% | 4.29% | 2.89% | 2.45% | 4.49% |
Insights
In beta| Jun 2018 | Aug 2021 | |
|---|---|---|
| DocExa Registered Doctors count |
|
|
| Mediapp Pharmacy / Retailer Network count |
||
| Makebot Online Subscriptions count |
||
| Makebot School Deployment count |
||
| Makebot Student Touchpoints count |
||
| Makebot Teachers Trained count |
||
| Mediapp Stockists count |
||
| Vodo Pharma Partners count |
||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
14 Jul - In accordance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018; we hereby confirm that the Company has not received any demat/remat requests …
-
Closure of Trading Window
26 Jun - Trading window closed from 1 July 2026 until 48 hours after Q1 FY26 results.
-
Announcement under Regulation 30 (LODR)-Acquisition
18 Jun - Board approved conversion of ₹12.64 crore loan into equity in subsidiary Miljon Mediapp, completing by 31 July 2026.
-
Grant Of Options Pursuant To The "Global Space Technologies Limited - Employees Stock Options Scheme - 2018"
1 Jun - Company corrected ESOP grant number to 4,25,000 options from 4,90,000.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
29 May - Submitted Annual Secretarial Compliance Report for FY ended March 31, 2026, on May 29, 2026.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Aug 2021TranscriptAI SummaryPPT
-
Feb 2021TranscriptAI SummaryPPT
-
Jan 2021TranscriptAI SummaryPPT
-
Nov 2020TranscriptAI SummaryPPT
-
Sep 2020TranscriptAI SummaryPPT
-
Jun 2020TranscriptAI SummaryPPT
-
Jun 2020TranscriptAI SummaryPPT
-
Jun 2018TranscriptAI SummaryPPT
-
Apr 2018TranscriptAI SummaryPPT
Business Overview:[1][2]
GSTL is an AI-powered healthcare ecosystem integrating digital health and pharma tech for patients, providers, and pharmaceutical companies. It also provides customized software solutions and technology-enabled business enhancement services across the IT and communication industry.